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ABSTRACT
BUILDING A METABOLIC BRIDGE BETWEEN GLYCOLYSIS AND SPHINGOLIPID
BIOSYNTHESIS: IMPLICATIONS IN CANCER
Morgan L. Stathem
08/07/2014
Cancer therapeutics has seen an emergence and re-emergence of two metabolic fields in
recent years, namely bioactive sphingolipids and glycolytic metabolism. Anaerobic glycolysis
and its role in cancer has been recognized in cancer biology over 90 years. In recent decades, the
role of sphingolipids in cancer cell metabolism has gained recognition, notably ceramide’s
essential role in programmed cell death and the role of the glucosylceramide synthase (GCS) in
chemotherapeutic resistance. Despite this knowledge, a direct link between these two fields has
yet to be concretely drawn. Herein, we show that in a model of highly glycolytic cells, generation
of the glycosphingolipid (GSL) glucosylceramide (GlcCer) by GCS was elevated in response to
increased glucose availability, while glucose deprivation diminished GSL levels. This effect was
likely substrate dependent, independent of both GCS levels and activity. Conversely, leukemia
cells with elevated GSLs showed a significant change in GCS activity, but no change in glucose
uptake or GCS expression. In a leukemia cell line with elevated GlcCer, treatment with inhibitors
of glycolysis or the pentose phosphate pathway significantly decreased GlcCer levels. When
combined with pre-clinical inhibitor ABT-263, this effect was augmented and production of proapoptotic sphingolipid ceramide increased. Taken together, we have shown that there exists a
definitive link between glucose metabolism and GSL production, laying the groundwork for
connecting two distinct yet essential metabolic fields in cancer research. Furthermore, we have
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proposed a novel combination therapeutic option targeting two metabolic vulnerabilities for the
treatment of leukemia.
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INTRODUCTION
Sneaky, smart, conniving, stubborn. Evasive and yet ever-present. Our knowledge of “the
emperor of all maladies” [1] has never run deeper, yet despite profound advances in its detection
and treatment, most standard of care regiments are subject to grueling side effects at best,
eventual resistance at worst. In its quest for novel treatment targets, cancer therapeutics has come
full circle to revisit a metabolic hallmark of cancer cells first brought to light by Otto Warburg
over 80 years ago, that of aerobic glycolysis. While revolutionary at the time, it is now
recognized that this aberration is only a small piece of the puzzle of deregulated cancer cell
metabolism. More recently, it has been shown that tumor cells present with altered sphingolipid
profiles at baseline, in correlation with increasing aggressiveness and in response to
chemotherapeutics. Despite these two seemingly unrelated facets of metabolism, it is understood
that no metabolic alteration in cancer stands as an island unto itself, and we present data to show
that the areas of glycolytic and sphingolipid metabolism are no exception to this rule.

Alterations in Cellular and Systemic Glucose Metabolism in Cancer
The role of aerobic glycolysis in cancer has been extensively reviewed by experts in the field
of cancer metabolism [2-8]. To attempt to summarize this work would not give justice to the
wealth of knowledge that exists, however a succinct overview of glycolytic metabolism in
relation to the current topic will be presented here.
In “normal” (differentiated, non-replicating) cells under normoxic conditions, the majority of
the cell’s energy demands are generated through oxidative phosphorylation in the mitochondria,
using reducing equivalents such as NADH and succinate generated through upstream catabolic
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pathways such as glycolysis, beta oxidation and the tricarboxylic acid (TCA) cycle to form ATP.
Only under conditions where oxygen is limiting do these cells revert to glycolytic metabolism for
ATP production and subsequently produce excess amounts of lactate. On the other hand,
transformed cells do not follow the same rules of metabolism. The Warburg Effect states that
cancer cells take up increased amounts of glucose compared to their non-transformed
counterparts and preferentially utilize glycolytic metabolism to produce ATP, even in the
presence of oxygen, a phenomenon termed aerobic glycolysis [9-11]. Enigmatically, however, the
alternative energetic pathway, oxidative phosphorylation, produces significantly more ATP than
aerobic glycolysis per molecule of glucose. This begs the question: why do cancer cells
preferentially utilize glycolysis, a “less efficient” pathway? Furthermore, contrary to what
Warburg originally postulated, a great majority of cancer cells retain the ability utilize oxidative
phosphorylation (OXPHOS) via functional, or mainly functional, mitochondria [12]. In contrast
to initial beliefs, the purpose for shifting to aerobic glycolysis lies beyond fulfilling the energy
requirements of rapidly proliferating cells; rather, increased glycolytic metabolism is utilized to
provide the raw materials needed for rapid growth in the form of anaplerotic substrates. These
substrates are produced through shuttling of glycolytic pathway intermediates into a variety of
other metabolic pathways, such as the pentose phosphate pathway (PPP), the TCA cycle,
nucleotide biosynthesis and glycogen synthesis [4, 5, 7, 8]. As will be discussed in further detail,
one such pathway has remained largely unexplored, that of sphingolipid biosynthesis.
In addition to the role of metabolic alterations at the cellular level in cancer cells, evidence
has mounted at both the clinical and epidemiological level that systemic alterations in metabolism
may also play a role in oncogenesis, progression and response to treatment. Obesity,
hyperglycemia, hyperlipidemia and insulin resistance are correlated with increased risk of cancer
development, more rapid disease progression and poorer response to treatment [13]. These
disease states are associated with elevated circulating glucose and insulin levels. As such, one
proposed mechanism for the increased incidence of cancer in these patients is activation of
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mitogenic signaling pathways by glucose and insulin-like growth factors 1 (IGF1) through the
IGF1 receptor (IGF1-R) [14], in addition to increased availability of glucose for uptake by cancer
cells preferentially utilizing glucose metabolism. Retrospective studies have also shown that
patients being treated with metformin and statins have a decreased incidence of cancer, although
at least in some cancers this is believed to be independent of their effects on glucose and
cholesterol metabolism, respectively [10, 11, 15-17]. Finally, both in vitro and in vivo studies
have shown that both a ketogenic diet, which lowers circulating glucose levels [18], and caloric
restriction [19] sensitize cancer cells to chemotherapeutics. Collectively, these studies indicate
that alterations in metabolism at the systemic level, more specifically those which increases blood
glucose levels, can promote oncogenesis and that metabolic therapeutics may serve to reverse this
effect.

Cancer Metabolism Extended: the P entose Phosphate Pathway and Glycogen Synthesis in
Cancer
While one of the most well-known metabolic hallmarks of transformed cells is increased
utilization and reliance on glycolysis, the purpose of this aberration is merely as a conduit to
further the overall goals of the cancer cell. In contrast to its role in “normal” cells, where it
primarily serves to generate both ATP and reducing equivalents for OXPHOS, increased aerobic
glycolysis in neoplastic cells functions to provide anaplerotic intermediates for shunting into
various metabolic and anabolic pathways to support the requisite increase in biomass of the
rapidly proliferating cell. The pentose phosphate pathway (PPP) is one of the key metabolic
pathways [2, 8, 20]. Briefly, the PPP receives intermediates from glycolysis (primarily glucose-6phosphate (G6P), fructose-6-phosphate (F6P), and glyceraldehyde-3-phosphate (G3P)) for
production of NADPH and ribose-5-phosphate (R5P). R5P is the precursor utilized in nucleotide
biosynthesis to maintain rapid DNA synthesis in the highly proliferative phenotype. NADPH is
an essential reducing agent in lipid and nucleotide biosynthesis, in addition to being a critical
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cellular antioxidant. As testament to its key role in cancer cell metabolism, and glycolysis’ role as
a supplier rather than an effector, it was shown that decreased PPP flux and concomitant
increased glycolytic metabolism through increased pyruvate kinase M21 (PKM2) activity resulted
in decreased tumor growth in a xenograft model [21]. Furthermore, increased activity glucose-6phosphate dehydrogenase (G6PD)2, either through overexpression or inhibition of negative
feedback, was sufficient to transform murine NIH-3T3 fibroblasts and promote tumorogenesis in
mice [22]. In relation to the current study, NADPH formation is essential for multiple aspects of
sphingolipid metabolism: both in lipid biosynthesis, in forming the fatty acid chain to be added to
sphingosine to form dihydroceramide, and in de novo ceramide synthesis itself (Fig. 1).
While many other facets of oncogenic metabolism have been the topic of intense research, the
role of glycogen synthesis in this phenotype remains comparatively less explored. As early as
1925, it was shown that highly glycolytic tumor cells present with elevated glycogen levels [23],
a phenotype now recognized as a hallmark of many clear cell carcinomas/sarcomas [24-28]. More
recent studies have suggested that glycogen formation may function as a protective mechanism
by serving as a store of glucose molecules to fuel anaerobic glycolysis during times of external
stress [29]. In studies of tumor cell hypoxia, it has been shown that glycogen synthase is initially
upregulated in response to oxygen deprivation, in [30-33], with a delayed increase in glycogen
phosphorylase after prolonged hypoxia [34]. Furthermore, inhibition of glycogen phosphorylase
in pancreatic tumor cells resulted in decreased glucose oxidation, and subsequent reduction in
fatty acid and nucleotide biosynthesis [35]. This protective mechanism would arguably play a
more important role in the pathogenesis of solid tumors, which are more susceptible to areas of
oxygen deprivation; however, evidence does suggest that leukemic cells may be exposed to areas
of hypoxia in the bone marrow microenvironment as well [36, 37]. Glycogen formation is
1

PKM2: pyruvate kinase isoform M2; catalyzes the rate-limiting, ATP-generating step of glycolysis in
which phosphoenolpyruvate (PEP) is converted to pyruvate; the M2 form is found in self-renewing cells,
and tumor cells
2
G6PD: glucose-6-phosphate dehydrogenase: the rate-limiting enzyme for entry of G6P into the PPP (via
conversion of G6P to 6-phosphogluconate)
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catalyzed by glycogen synthase (GS), through addition of UDP-glucose to existing glycogen
polymers. UDP-glucose formation depends on the formation of UTP, which relies on nucleotide
biosynthesis for its formation, itself being fueled by production of intermediates from the PPP
(see a simplified diagram below). Although to the best of our knowledge there are no studies that
directly measure the level of UDP-glucose in neoplasms, studies in animal models of diabetes,
which also take up elevated levels of glucose, present with elevated levels of UDP-glucose [38,
39]. Lastly, the regulation of GS by glycogen synthase kinase (GSK) has recently become a topic
of interest in cancer signaling, though its exact role in carcinogenesis is still largely unclear and
thus will not be discussed here (a review on the topic can be found in ref. [40]).

Glycolytic Inhibitors / PPP Inhibitors in Cancer
Given the significant role that aberrant metabolism plays in the neoplastic cell phenotype,
development of therapies targeting the key control enzymes in the aforementioned pathways is
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being actively pursued [2, 41-43]. Current agents are comprised of both pharmacological and
RNAi mediated inhibition of nearly all facets of neoplastic metabolism, utilizing both established
metabolic therapies and novel rational drug design [2].
Despite promising results at the pre-clinical and clinical level, targeting the deregulated
bioenergetic and anabolic pathways in neoplastic cells is subject to the same critical pitfall as
genotoxic therapies, which themselves target cells of the highly proliferative phenotype.
“Normal” rapidly dividing cells, such as bone marrow-derived cells or gut epithelium, are subject
to the non-discriminant effects of cytotoxic drugs, resulting in sometimes severe side effects
associated with chemotherapy. Common short-term effects includenausea, emesis, fatigue,
diarrhea, cachexia, peripheral neuropathy, myalgia, alopecia and myelosuppression; long-term
side effects may include cardiotoxicity, ovarian failure in women, sterility in men, chemotherapyinduced leukemia and cognitive dysfunction [44], notwithstanding drug-specific toxicities and
side effects. Furthermore, activation of T lymphocytes (i.e. rapid clonal expansion) relies on
increased glucose uptake and reliance on aerobic glycolysis [45]. T lymphocytes play a key role
in immune-derived targeting and eradication of cancer cells through recognition of tumorassociated antigens [46]. Tumor cells have been shown to avoid detection from the immune
system by inducing apoptosis of immune cells such as lymphocytes and antigen presenting cells,
both in the surrounding microenvironment and systemically [47-50]. Further dampening of this
immune response via inhibition of biometabolic pathways could be seen as adding insult to
injury. However, it is proposed that there exists a therapeutic window in which treatments could
target neoplastic/malignant cells, for example through isoform-selective therapies or careful drug
titrations (reviewed in [51]). Another alternative involves the use of combinatory therapies, with
one advantage being a lower effective dose of each individual drug, an approach which is
commonplace in modern day chemotherapeutics [52]. A growing number of studies point to the
therapeutic potential of combining metabolic inhibitors with targeted therapies [53, 54], such as
the combination of hexokinase-II inhibitor 3-BrOP with mTOR inhibitor rapamycin [55]. In the
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current study, we have provided support for this approach, in showing potent synergism exists
between two metabolic inhibitors, 2-deoxyglucose3 (2-DG) and 6-aminonicotinamine4 (6-AN),
and ABT-2635, a targeted inhibitor of the pro-apoptotic BCL2 family.

Sphingolipids: Membranes and More
Sphingolipids, originally sphingosin or “sphinx-like”, were named in respect of their
enigmatic and complex nature by Johann Thudicum almost 150 years ago. Since that time, it has
been established that hundreds of higher order sphingolipid species exist, thousands when taking
into account varying chain lengths, a statistic daunting enough to scare off even the most
dedicated of biologists. However, their role in cancer pathogenesis is undisputed, so though they
may be the in-laws of the cancer biology family, they are here to stay and thus must be discussed.
After a few glasses of wine, you may even grow to enjoy them. For the purpose of this
discussion, a brief overview of sphingolipid metabolism will be presented as it relates to the
current study. For a more thorough understanding of this topic, consult your nearest black hole
(or the following review by Gault, Hannun and Obeid [56]).
Sphingosine, an amino alcohol of 18 carbons formed from the condensation of palmitoyl
CoA and serine, is the backbone of the entire sphingolipid family. Important players in this
family are:
i)

ceramide, formed via N-acylation of a fatty acid chain (14-26 carbons) to the
amide group of sphingosine by ceramide synthase (CerS); the central hub of
all sphingolipid metabolism
ii) sphingomyelin (SM), a key membrane phospholipid, formed via addition of
phosphocholine (or less commonly phosphoethanolamine) to the C1
hydroxyl of ceramide via sphingomyelin synthase (SMS)

3

2-deoxyglucose (2-DG): inhibitor of the rate-limiting enzyme of glycolysis, hexokinase (HK) through
competitive inhibition with glucose
4
6-aminonicotinamine (6-AN): inhibitor of 6-phosphogluconate dehydrogenase, an enzyme of the PPP
which catalyzes the conversion of 6-phosphogluconate to ribulose-5 phosphate
5
ABT-263 (navitoclax): structural analog of ABT-737; inhibitor of the BCL2 family anti-apoptotic
proteins, namely Bcl-2, Bcl-w and Bcl-xL; induces apoptosis
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iii) glucosylceramide (GlcCer), formed via addition of UDP-glucose to ceramide
via glucosylceramide synthase (GCS); point of entry into the higher order
glycosphingolipids
iv) sphingosine-1-phosphate (S1P), formed via addition of a phosphate group to
sphingosine by sphingosine kinase

Ceramide. Siskind et al. 2008

Under normal homeostatic conditions, ceramide can be generated via three pathways: 1) de novo
synthesis 2) sphingomyelin hydrolysis 3) the salvage pathway (S1P breakdown). The de novo
pathway relies on a critical enzyme, ceramide synthase (CerS), to catalyze the addition of a fatty
acyl group to sphinganine to form (dihydro)ceramide (Fig. 1). As alluded to prior, part of the
complex nature of sphingolipids is their ability to differ by fatty acid chain length. Six different
isoforms of CerS exist and although some overlap exists, each isoform preferentially utilizes a
specific fatty acyl chain length(s) [57]. For example, CerS5 preferentially uses long-chain fatty
acids of 14 or 16 carbons to form either C14-Ceramide or C16-Ceramide. This has important
implications for targeted therapies against sphingolipid enzymes, as it is postulated that
ceramides (and derivatives such as glycosphingolipids) may play markedly different roles
depending on the fatty acid chain length [58-60].
Ceramides are synthesized de novo in the endoplasmic reticulum (ER), then transported to
the Golgi. On the cytoplasmic face of the Golgi, GCS catalyzes the addition of UDP-glucose to
form GlcCer. An important implication of this localization is that GCS has access to cytoplasmic
contents and is not restricted to their transport across the Golgi membrane, a fact that will be of
importance in discussion of its hypothesized role in cancer cell metabolism.
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In addition to their role in regulation of membrane dynamics, sphingolipids are bioactive
lipids involved in intracellular signaling, including roles in inflammation, cellular proliferation,
oxidative stress and cell death. As defined by Hannun and Obeid, sphingolipids are regarded as
bioactive due to the observation that “changes in (their) levels result in functional consequences”
[61]. Among the many cellular functions in which sphingolipids play a role, one of the best
characterized is their role in programmed cell death, or apoptosis [62]. Over 20 years have passed
since the seminal work linking ceramide production to apoptosis was first published [63]. Since
that time, there has been no shortage of studies linking cytokines, external stressors and apoptotic
stimuli to production of ceramide and induction of apoptosis. Briefly, an external stimulus, such
as TNF-α, leads to production of ceramide via activation of a metabolic enzyme, such as
sphingomyelinase, which degrades SM to ceramide. Ceramide may then exert its proapoptotic
effects through multiple mechanisms: 1) formation of ceramide-enriched domains and subsequent
modulation of receptors or signaling molecules or 2) contributing to induction of mitochondrial
outer membrane permeabilization (MOMP) through formation of ceramide channels in the
mitochondrial outer membrane (MOM). (reviewed in [64]). The control of intracellular ceramide
in response to cytotoxic agents is an important determinant in the outcome following a cytotoxic
insult and thus has been implicated in a variety of disease states, cancer notwithstanding.

Glycosphingolipids and Cell Signaling: Implications for Cancer
In addition to their well-characterized role as structural components in the plasma membrane,
certain species of GSLs have been widely implicated as pro-proliferative bioactive lipids in a
variety of pathologies, including metabolic, kidney, and cardiovascular diseases, in addition to
neoplasms [65-67]. Most evidence has pointed to the role of lactosylceramide and gangliosides as
the major GSL players in this phenotype. GSLs have been shown to act as key players in various
cellular signaling pathways, through formation of GSL micro- and macrodomains in the plasma
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membrane, termed “glycosynaptic membranes” [68], in which they interact with transmembrane
growth factor and cytokine receptors [69, 70], intracellular signal transducers [71], and cell
adhesion proteins [72, 73].
Of particular interest in recent decades is the role of GSLs in cancer. Clinical evidence shows
that tumor cells have distinct glycosphingolipid profiles compared to non-transformed cells [50,
74, 75], a phenotype associated with aberrant cell-cell adhesion and intracellular signaling, which
play a significant role in tumor progression, metastasis, and response to treatment [76]. Much
progress has been made in elucidating the mechanisms by which GSLs play a pathogenic role in
solid tumors (for review, see ref [68, 77, 78]). In brief, such mechanisms include: i) association of
GSLs with cell surface receptors and subsequent modulation of cellular signaling pathways, such
as inhibition of tyrosine kinase activity of EGFR in breast cancer cells [74]; ii) modulation of
integrin receptor function and subsequent control of invasion and motility, such as in bladder
cancer [73]; iii) regulation of non-receptor intracellular signaling proteins, such as c-Src and Rho
in melanoma [71]; and iv) “shedding” of GSLs into the extracellular tumor environment,
inhibiting localized immune response and effectively paving the way for invasion and metastasis
[47, 49]. Similarly, hematological malignancies have been found to have distinct GSL expression
patterns in relation to disease subtype [79-84], although in contrast to solid tumors, less is known
about their functional role in pathogenesis of blood cancers. As is recurrently the case in cancer
biology, growing evidence suggests that the effect of GSL on cancer pathogenesis is both tumorand GSL-species specific [85]. GSLs themselves are an extremely complex group of lipids
composed of thousands of higher order species [86]. Despite this complexity, certain GSL subspecies have garnered particular interest due to their variable expression in tumors, namely those
of the ganglioside6 family. While overexpression of GSLs is associated with increased metastatic
potential in some cancer types such as lymphoma and melanoma, it is inversely correlated with

6

Ganglioside: a glycosphingolipid composed of a lactosylceramide backbone with the addition of sialic
acid moieties
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invasion and metastatic potential in others, such as bladder and liver cancer (reviewed in [85]).
Nevertheless, while aberrant GSL expression is increasingly considered a hallmark of cancers and
may be useful as a biomarker in measuring disease progression, arguably one of those most
extensively studied aspects of sphingolipid biology in cancer is its role in chemotherapy-induced
apoptosis, or evasion thereof.
In addition to their established role in proliferation, invasion and metastasis in tumors, GSLs
have also been implicated in multidrug resistance (MDR). Treatment of cancer cells with
chemotherapeutics elevates levels of the proapoptotic sphingolipid ceramide in a multitude of
cancer cell lines during mitochondrial induced cell death [62, 64, 87, 88]. As a means of evading
cell death, many drug-resistant cell lines reduce cellular ceramide levels via metabolism to other
sphingolipid members, one such mechanism being conversion to GlcCer [65, 89].
Correspondingly, elevated levels of GCS and GlcCer are widely implicated in MDR in many
cancers [90, 91]. The mechanism behind this observed phenomenon has been well characterized
both at the in vitro and in vivo level. Briefly, a growing body of data suggests a strong
relationship between GCS, MDR1, p-glycoprotein, drug efflux and resistance. P-gp is a
membrane transport protein implicated in drug efflux-dependent and -independent resistance,
encoded by the MDR1 gene. P-gp is also responsible for the transport of GlcCer from the
cytosolic to luminal face of the golgi membrane [92], where it can be converted to more complex
GSL species [93]. Studies have shown a direct correlation between increased drug resistance,
GCS expression and p-gp message and protein levels [94]. It has also been shown that both
GlcCer and GCS lead to increased MDR1 expression, through c-Src and beta-catenin signaling
[91, 95]. This effect can be abated through pharmacological or genetic inhibition of GCS, which
also resensitizes resistant cells to chemotherapeutics [96, 97]. Taken together, GCS plays a clear
role in cancer pathogenesis and consequently has been an attractive target for the development of
anti-neoplastic pharmaceuticals as both a primary treatment and a combinatorial treatment with
cytotoxic therapies for the treatment of drug-resistant malignancies [98].
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As a final note, it is worth mentioning that the sphingolipids lactosylceramide and
sphingosine-1-phosphate have been widely implicated in tumoro- and leukemogenesis, including
roles in proliferation, metastasis and resistance, however are outside the scope of the current
review. The reader may reference an in-depth review by Ogretman and Hannun for more
information on this topic [99].

GCS Inhibitors in Cancer
In keeping with the growing body of evidence implicating GSLs in cancer pathogenesis,
significant investment has been made into the development of targeted GCS inhibitors. Despite
resounding evidence that GCS acts as a potent sensitizing agent to cytotoxic and metabolic drugs,
there persists conflicting views in the literature as to the exact mechanism by which GCS
inhibitors exert their effects, and to what end sphingolipid metabolism plays a role. For this
reason, a very brief overview of the evidence surrounding this topic will be presented, as the field
will surely evolve in its understanding in the coming years.
As previously discussed, there exists a positive correlation between p-gp and GCS levels in
MDR. In targeting GCS as a means of reversing MDR, it has been shown in a wide range of
cancer types that pharmacological and genetic inhibition of GCS synergizes with both standard of
care chemotherapeutics [100-104] and with metabolic inhibitors such as resveratrol [105]. Given
the relationship between GCS and p-gp in MDR, in addition to the fact that ceramide analog GCS
inhibitors7 are also substrates of p-gp, the question was posed as to whether MDR reversal was
truly a result of GCS, and not p-gp, inhibition. Evidence exists for both the former [106] and the
latter [98, 107], indicating that indeed this topic must be explored in greater depth.
What is almost undisputed in the literature, however, is that the sensitizing effect of GCS
inhibition on cyototoxic therapies occurs almost exclusively in cells with established drug
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Ceramide analog GCS inhibitors: as their name suggests, these inhibitors are ceramide analogs which
compete for binding on GCS;
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resistance, as opposed to the parental, drug-sensitive cell line [98, 108]. In fact, one study has
shown that treatment of non-resistant cells with PDMP and PPMP, ceramide analog inhibitors of
GCS, results in resistance to the genotoxic drugs doxorubicin and cytarabine in a leukemia model
[109], a phenomenon confirmed by data in the present study.
While the mechanistic basis of sensitization by GCS inhibitors remains to be and must be
elucidated, the fact remains that an overwhelming amount of evidence points to its efficacy. It is
for this reason that its use in the clinic for the treatment of drug-resistant cancers has been
advocated. The GCS inhibitor eliglustat tartrate (Genz-112638) is currently in phase III clinical
trials for Gaucher’s Disease8 patients, and seems to be both effective and well tolerated. As such,
this could be a promising option for the first human trials therapeutically targeting GCS,
particularly in the context of drug resistant cancer. It should be noted, however, that because
Genz-112638 [110] is a substrate of p-gp, it very poorly penetrates the blood brain barrier and
thus would not be a viable option for the treatment of primary or metastatic brain tumors.
However, design of a GCS inhibitor that would cross the BBB is currently an active area of
research [111].

Cross-talk between Glycolysis and Sphingolipid Biosynthesis
Given that GCS utilizes UDP-glucose to generate GlcCer, it would follow that increased
glucose availability might elevate GSL levels. Despite this rather straightforward observation, a
limited amount of data exists on the potential connection between these two entities, none of
which has been evaluated in transformed cells. In vitro work has shown that renal epithelial cells
cultured in high glucose have both elevated GlcCer and increased proliferation [38]. Work in rat
models of type 1 diabetes mellitus (DM1) indicates a correlation between glucose uptake and
GSL production. In these models, both UDP-glucose [112] and GSL levels [38, 39] are elevated

8

Gaucher’s Disease: an autosomal recessive lysosomal storage disorder due to a defiency of GBA, leading
to accumulation of GlcCer in certain organs
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in the kidney in response to increased plasma concentrations of glucose. Conversely, inhibition of
GSL production via targeting GCS improves glucose tolerance in animal models of DM1 [113].
Furthermore, reduction of GSL levels via inhibition of GCS increases both glucose uptake and
glycolytic metabolism in leukemia cells [114], suggesting that a compensatory mechanism may
exist by which the cell restores GSL levels through increased uptake and metabolism of the
requisite substrates. Although these studies establish a connection between glucose availability,
substrate production and GSL levels, they are inherently confounded by either: 1) the presence of
disease states, for which the presence of external variables cannot be excluded or 2) the aberrant
signaling pathways characteristic of transformed cells which undoubtedly influence glycolytic
metabolism beyond glucose uptake.

Conclusions
Despite the fact that increased glucose uptake and utilization is a hallmark of most cancers,
and elevated glycosphingolipids are widely accepted as a prognostic marker of cancer progression
and metastatic potential, an objective relationship between the two has yet to be drawn. Herein
we have established a link between the distinct, yet clearly interrelated metabolic fields of
glycolytic and glycosphingolipid metabolism. We demonstrate that increasing glucose uptake and
utilization in a non-transformed cell line, FL5.12, is sufficient to increase the levels of GSL,
while withdrawing glucose from these same cells causes their dramatic depletion. Inhibition of
glycolysis and the PPP is sufficient to deplete GSL levels in the same manner in both FL5.12 cell
lines. Furthermore, we also present findings that this link persists in hematological malignancies
and that manipulation of glycolytic and pentose phosphate pathway metabolism influences GSL
levels in a leukemia cell line. Finally, we show that in a leukemia cell model, metabolic inhibitors
2-DG and 6-AN synergize with pro-apoptotic BCL-2 inhibitor ABT-263 in inducing apoptosis.
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Overall, these data demonstrate a clear link between glucose uptake and utilization and the
production of glycosphingolipids.
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Figure 1: An overview of sphingolipid metabolism.
Formation of ceramide occurs through the de novo pathway (1), SM hydrolysis pathway (2), the
salvage pathway (3), or β-Glucocerebrosidase (GBA) breakdown (4). The ratio of ceramide to
glucosylceramide is an important factor in the survival of cells. Glucosylceramide is formed
through addition of UDP-glucose to ceramide by glucosylceramide synthase (GCS) or the
breakdown of lactosylceramide.

16

MATERIALS AND METHODS
Cell Culture and Reagents
FL5.12 WT and HG cells were kindly provided by Dr. Jeffrey Rathmell (Duke University
Medical Center, Durham, NC) [115]. Human leukemia cells were purchased from ATCC. All
cells were maintained in HyClone RPMI 1640 (Thermo Scientific #SH 30027) medium
containing 10% FBS supplemented with 2 mM L-Glutamine, 10 mM HEPES (Gibco 15630-80)
and 1X pen-strep (Gibco 15140-122); FL5.12 cells were additionally supplemented with 2 ng/ml
recombinant mouse IL-3 and 1X β-mercaptoethanol. FL5.12 cells were maintained in the log
growth phase between 5x105 and 2x106 c/ml. Leukemia cells were maintained in the log growth
phase between 1x105 and 2x106 c/ml.

Cell Viability Assay
Cells growing in the log phase were seeded in 96- well dishes (2,500 FL5.12, U937, or 5,000 OCI
AML 3 or 7,500 K562 cells per well) and immediately treated with the indicated drug
concentrations in a total volume of 200 μl per well. All treatments were done in triplicate. 2-DG
(#14325) and 6-AN (#10009315) were obtained from from Cayman and ABT-263 (cat#CTA263) from Chemietek (Indianapolis, IN, USA). Cells were treated for 48 hours, then incubated
with 10% (20 μl) Alamar Blue reagent (cat#DAL1100) from Invitrogen (Grand Island, NY,
USA). for 4 hours. Fluorescence of Alamar Blue reduction was determined on a BioTek HT
Synergy plate reader (540 nm excitation, 594 nm emission). Wells containing only complete
RPMI media and vehicle plus 20 μl of Alamar Blue were averaged and subtracted from all
experimental readings. Drug treatment regimens were then normalized to either vehicle treated
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cells or to wells containing only the IC30 of the indicated drug using a high-throughput method in
excel (see below). Each graph shown is a representative experiment of at least three biological
replicates unless otherwise indicated.

Western Blot Analysis
5x106 cells were harvested and lysed via sonication for 30s in 350 μl of RIPA lysis buffer (NEBL
#9806S) with 100X protease and phosphate inhibitors. Protein concentrations were determined
using BCA protein assay reagent from Pierce (#23223 and #23224). Cell homogenate was spun
for 5 minutes at 500xg to pellet unlysed cellular debris. Supernatant was transferred to a new
tube. Briefly, supernatant was diluted 1:10 and 25 μl of this dilution was added to 475 μl of BCA
reagent. Pre-diluted BSA protein standards were utilized for preparation of a standard curve. 25
μl of BSA standard and 25 μl of lysis buffer was added to 450 μl of BSA reagent. Standards and
unknowns were then vortexed to mix and incubated in a 37° water bath for 30 minutes. 200 μl of
standard and unknown were then plated in duplicate on a 96-well plate and measured on a
spectrophotometer at 562 nm. Unknown values were extrapolated to the standard curve for
quantification. Using these values, protein was diluted to 2 μg/ml. 40 μg (20 μl) of total protein
was used for standard western blot procedure. Samples were boiled at 98° for 5 minutes before
being run on SDS-PAGE gel (BioRad #345-0033) at 165V for approximately 30 minutes. The gel
was then transferred using the iBlot Transfer System (Novex). Membranes were blocked in TBST with 5% milk for 1 hour at room temperature. Primary antibody was added in the following
dilutions: 1:1000 anti-GLUT1 (Santa Cruz #SC-7903), 1:2500 anti-HK1 (Cell Signaling #2024);
1:10,000 anti-actin (Sigma #A5441), 1:10,000 anti-tubulin (Sigma #T5168). Anti-mouse and antirabbit were added at a dilution of 1:10,000. Chemiluminescent detection was performed using
Pierce ECL Western Blot Substrate (#32106) from Thermo Scientific according to
manufacturer’s protocol.
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In Situ Glucosylceramide Synthase Activity Assay
5mg NBD-C6-Ceramide complexed with BSA (Life Technology #N22651) was dissolved in 150
μl sterile dH2O (0.5mM NBD-C6-Ceramide and 0.5mM BSA) and stored at -20°C. 1x106 cells
were plated in a 6-well plate in 2ml of complete RPMI 1640 media. 20 μM PDMP was added to
the appropriate wells; remaining cells received DMSO as vehicle. Cells were incubated for 2
hours at 37°C. All cells then received 2uM of NBD-C6-Ceramide and were incubated at 37°C for
30 minutes. Cells were collected, spun at 1000xg for 5 min at 4°C, and supernatant was removed.
Cells were washed 1X by adding ice-cold PBS (1000xg, 5 min, 4°C). Supernatant was removed.
Lipids were extracted by Bligh and Dyer method [116]. Briefly, cells were resuspended with 260
μl of ice-cold PBS and transferred to glass tubes. 666 μl of methanol was added to the cells and
vortexed 2x30s. Cells were then kept on ice for 10 min. 333 μl of chloroform and 333 μl of water
was added to tubes, which were vortexed two times for 30s then spun at 3000rpm for 5 min at
room temperature. The lower phase (containing the lipids) was transferred to a new set of glass
tubes and lipids were dried down by nitrogen gas. Lipids were then resuspended in 30 μl of
chloroform/methanol (2:1, v/v) and loaded onto TLC plates (Millipore #1.05644.0001) for
separation. NBD-Glycosphingolipids were used as standards. The chromatogram was developed
in a solvent system consisting of chloroform/methanol/30%ammonium hydroxide/water
(350:150:18:7: vol/vol). TLC plates were scanned on a BioRad phosphorimager. Band density
was quantified by Quantity One software (count/mm2). NBD-GlcCer were normalized to total
(NBD-Ceramide + NBD-GlcCer), and the normalized to total cell number and time.

Quantitative Real-Time Reverse Transcription PCR
Total RNA was extracted using EZNA Total RNA Kit I (OMEGA bio-tek #R6834) according to
the manufacturer’s protocol. The concentration and quality of total RNA preparations were
evaluated by NanoDrop. cDNA was synthesized from 1 ug of total RNA using the iScript cDNA
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Synthesis Kit for first-strand synthesis (BioRad # 170-8890). Quantitative real-time PCR (qPCR)
was performed on a Bio-Rad CFX96 Real-Time detection system using SsoFast EvaGreen
Supermix (BioRad # 172-5202). Standard reaction volume was 25 μl containing 12.5 μl
Supermix, 9.5 μl dH2O (Sigma), 400 nM specific oligonucleotide primers, and 25 ng of cDNA
template. β-Actin was used as reference gene. The PCR reaction was carried out as follows for
UGCG, GBA and β-actin: enzyme activation 95°C, 30s; denaturation 95°C, 5s; annealing 60°C
5s; 40 cycles total. For FL5.12 cells, the ΔΔCT method was used, and HG was normalized to
WT. For leukemia cells, absolute quantification of expression was calculated via normalization to
a previously validated standard curve for β-actin. Primers were validated for temperature and
efficiency prior to use in qPCR. Primer sequences are as follows:
Gene

Sense

Anti-Sense

hACTB

ATTGGCAATGAGCGGTTCC

GGTAGTTTCGTGGATGCCACA

hUGCG

GAATGGCCGTCTTCGGGTT

AGGTGTAATCGGGTGTAGATGAT

hGBA

CCGATGGCTCTGCTGTTGTG

CAGGTAGGTGTGAATGGAGTAGC

mUGCG

CCTTGTTCGGCTTCGTGCTCTTC

TGCTATACGGCTGTTTGTCTGTTGC

mGBA

TGGATGCTTATGCTAAGTATGG

CACGGGAAATGAAGTCTCTCTG

mACTB

AGATTACTGCTCTGGCTCCTAG

CCTGCTTGCTGATCCACATC

Glucose Uptake
1x106 cells were plated in glucose-free RPMI 1640 media supplemented with 10% dialyzed FBS.
Cells were incubated at 37°C for 30 minutes following plating to allow equilibration with media.
Following incubation, cells were given 25μl of 14C deoxy-glucose (0.1μCi/μl) for one hour, then
washed three times with ice cold PBS. Cells were lysed in 500 μl 0.1% SDS. 400μl of lysate was
added to 5ml Microscint 40 scintillation fluid (Perkin Elmer) and mixed well by shaking. Counts
were measured on a Tri-Carb 2910 liquid scintillation analyzer (Perkin Elmer). Remaining lysate
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was quantitated with the BCA Assay as described above. Counts were normalized to μg protein
concentration.

Intracellular Lipid Measurement
5x106 cells were seeded in 10 cm dishes containing complete RPMI without antibiotics and
treated with the indicated drug(s) or appropriate vehicle in biological triplicates. At the indicated
times, cells were harvested, washed two times in 5 mL of ice cold PBS, then cell pellets were
snap frozen in liquid nitrogen. Quantification of sphingolipid species was performed by the
Lipidomics Core Facility at the Medical University of South Carolina (MUSC) on a Thermo
Finnigan TSQ 7000, triple-stage quadrupole mass spectrometer operating in a Multiple Reaction
Monitoring (MRM) positive ionization mode as described [117]. Excess lipids were obtained and
extracted using the Bligh and Dyer method. Data were normalized to total lipid phosphate.

Statistical Analysis
A one-way ANOVA with Halm-Sidak post-test was used for samples n>2. A two-tailed t-test was
used for samples where n=2. Unless otherwise indicated: all data points represent the compilation
of at least three biological triplicates; data are represented as average +/- SD; dose-response
graphs are a representative graph of an experiment conducted in triplicate; significance was
dictated as having a p-value < 0.05.
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RESULTS
Glucose Availability Dictates Glycosphingolipid Levels in Highly Glycolytic Cells
In order to determine whether glucose availability in and of itself is sufficient to drive GSL
production we utilized the murine IL-3 dependent FL5.12 hematopoietic progenitor cell line overexpressing the glucose transporter Glut-1 and the rate-limiting glycolytic enzyme HK-1 (herein
FL5.12 HG) [115]

(Fig. 2A). This cell line represents a model of highly glycolytic cells

independent of intracellular or extracellular alterations seen in disease states. As expected,
FL5.12 HG cells took up 83-fold more glucose as compared to their wild-type counterparts (Fig.
2B). Furthermore, over-expression of HK1 in HG cells leads to a significant decrease in their
sensitivity to treatment with the HK-1 competitive inhibitor 2-DG (IC50=0.33 mM vs 1.7 mM for
wild-type and HG, respectively) (Fig. 4A). This was further confirmed by treatment of both cell
lines with a single dose 2-DG and determining the relative cell viability. At 1 mM of 2-DG the
cell growth of wild-type cells was inhibited by 65%, whereas HG cells were only inhibited by
27% (Fig. 2C).
Previous studies indicated that increased glucose availability resulted in increased GSL levels
in DM1 mice [39], therefore we assessed if the same phenomenon would occur in our model of
highly glycolytic cells. Indeed, increased glucose availability resulted in elevated GSL levels in
FL5.12 HG cells compared to wild-type cells (Fig. 3A). This led us to question whether glucose
withdrawal would correspondingly result in decreased GlcCer levels. Indeed, wild-type cells
withdrawn from glucose for 18 hours showed a marked decrease in GlcCer levels compared to
cells continuously cultured in glucose (Fig.3B).
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To investigate the extent to which glucose availability impacts enzymatic control of GlcCer
formation, we measured the expression and activity of GCS and β-Glucocerebrosidase (GBA),
the enzymes responsible for the anabolic and catabolic formation of GlcCer, respectively (Fig.
3C). Although GlcCer levels were dramatically elevated in HG cells over wild-type, increased
glucose availability did not significantly alter the expression of GCS or GBA (Fig. 3C).
Moreover, GCS activity was also not increased in FL5.12 HG cells compared to wild-type (Fig.
3D).
Collectively, these data indicate that glucose availability impacts GSL levels, and that in nontransformed cell lines increased GSL production appears to be a substrate driven process
relatively independent of GCS expression or activity.

Inhibitors of Glycolytic Metabolism and the Pentose Phosphate Pathway Decrease
Glycosphingolipid Levels
Given that glucose availability plays a clear role in GSL formation (Fig.2B and 3A), we
determined whether selective inhibition of bioenergetic pathways downstream of glucose uptake
would decrease GSL levels. FL5.12 cells were treated in a dose response manner with 2-DG or 6AN to establish the respective IC50 of each cell line for these inhibitors (Fig. 4A-B). WT and HG
cells were then treated for 8 hours with 2-DG or 6-AN IC50 and total hexosylceramide (glucosyland galactosylceramide) levels were measured via HPLC-MS/MS. As shown in Fig. 4C,
hexosylceramide levels decreased following treatment with 2-DG in both WT and HG cells.
Treatment with 6-AN also decreased hexosylceramide levels in both cell lines, however this
effect was blunted in HG cells, an interesting result given that HG cells were found to be slightly
more sensitive to 6-AN.
Overall, these data support the hypothesis that GSL levels are at least in part influenced by
the production of substrates produced via glycolysis and the pentose phosphate pathway.
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Glycosphingolipid Levels in Leukemia Cells are Primarily Dictated by GCS Activity
FL5.12 HG cells provided an excellent, syngeneic in vitro model for establishing a
relationship between increased glucose availability and GSL production, however they inherently
lack the aberrations in intracellular signaling present in cancer cells. In order to examine if this
relationship persists in transformed cells, we utilized four leukemia and lymphoma cell lines
(collectively “leukemia” cell lines for simplicity), U937, OCI AML3, RAJI and HEL (Fig. 5A).
Baseline GlcCer levels were measured via HPLC-MS/MS. GlcCer levels were elevated in U937
and OCI AML3 cell lines, while decreased in RAJI and HEL when compared to cultured human
cord blood CD34+ cells (CB12011A) (Fig. 5B). Given that increased glucose availability
elevated GlcCer levels in our model of highly glycolytic FL5.12 cells, we examined whether
leukemia cells with elevated GlcCer also took up more glucose.. U937 and OCI AML3 cells took
up elevated, albeit non-significant glucose compared to RAJI and HEL cells (Fig. 5C).
To elucidate the extent to which glucose availability correlates with enzymatic GlcCer
production in these cell lines, we again measured GCS expression and activity. Similar to FL5.12
cells, there was no significant change in the mRNA expression of either GCS or GBA across the
leukemia cell lines (Fig. 6A and 6B). In contrast to FL5.12 cells, however, GCS activity
positively correlated with GlcCer levels in our panel of leukemia cells (Fig. 6C). Collectively,
these results suggest that increased GlcCer levels in leukemia cell lines may be primarily
influenced by increased GCS activity. Glucose availability may influence baseline GlcCer levels
in some leukemia cells, perhaps through the production of substrates formed during and
downstream of glucose metabolism.

Treatment of Drug Sensitive Leuk emia Cells with Sublethal Doses of GCS Inhi bitors
Confers Resistance to Doxorubicin
A growing body of data indicates that GCS inhibition sensitizes to antineoplastic agents in
the context of MDR [89-93], while a recent study showed that in that context of drug-sensitive
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cells, it inhibition of GCS may play a cytoprotective role upon combination with genotoxic drugs,
such as daunorubicin [109]. Preliminary data from our lab provide circumstantial confirmation of
this result. To establish sensitivity to doxorubicin9, U937 and 5 other leukemia cell lines were
treated with increasing doses of doxorubicin and assayed for cell viability (data not shown).
While all cell lines tested were sensitive to doxorubicin treatment, U937 was among the most
sensitive, evidenced by 100% decrease in cell viability at 1 μM. In order to determine the effect
of GCS inhibition on sensitivity to doxorubicin, dose response assays in U937 cells were first
performed to establish the IC50 of doxorubicin (55 nM), PDMP10 (72 μM) and PPMP (11 μM)
(data not shown). U937 cells were treated with doxorubicin in a dose-response manner alone or in
combination with the IC30 of PDMP or PPMP. Cells were also treated with increasing doses of
PDMP or PPMP with addition of doxorubicin IC30. PDMP in combination with doxorubicin
resulted in marked resistance to the drug, and vice versa (Fig. 7A-B). The same result was seen
upon dose response treatment with PPMP, although in this case resistance was even more striking
(Fig 7C-D).
As a note with respect to these results, it should be acknowledged that while the calculated
IC30 of both PDMP and PPMP were used, in actuality the calculated inhibition was 5% and 50%,
respectively. These data are preliminary results, and will require optimization and duplication in
order to confirm.

Inhibitors Of Glycolysis and PPP Synergiz
Ceramide:Glycosphingolipid Ratios

e

with ABT-263 to Inc

rease

Anti-apoptotic BCL-2 family proteins are up-regulated in many cancers, especially leukemias
[118]. We have shown previously that that PDMP, an inhibitor of GCS activity, sensitizes U937

9

Doxorubicin is a derivative of daunorubicin, both being anthracyclines with anti-tumor properties.
Doxorubicin has a higher therapeutic index.

10

PDMP: a well-established ceramide analog inhibitor of GCS; PPMP is a derivative of PDMP with a
markedly higher potency
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cells to treatment with ABT-263, a small molecule inhibitor of anti-apoptotic BCL-2 family
proteins Bcl-2, BCL-xL and Bcl-w [103]. To evaluate whether inhibition of the proposed
metabolic pathways upstream of glycosphingolipid formation also synergize with ABT-263 in
killing leukemia cells, we tested the combination of 2-DG or 6-AN with ABT-263 in U937 cells.
Cells were treated in a dose-response manner for 48h, either with increasing doses of 2-DG and
the IC30 of ABT-263 or vice versa (Fig. 8A). The same treatment pattern was followed using 6AN and ABT-263 (Fig. 8B). The presence of 2-DG or 6-AN dramatically decreased the dose of
ABT-263 required to induce cell death. The IC50 for ABT-263 alone was 5 μM, however upon
addition of 2-DG decreased by 12.5-fold to 0.4 μM. Similarly, the IC50 of ABT-263 decreased
even more dramatically in combination with 6-AN, from 5μM to 0.15 μM, a 37-fold reduction.
The same phenomenon was observed when ABT-263 was added at a constant dose to increasing
doses of 2-DG or 6-AN, reducing the IC50 by 14-fold and 18-fold, respectively.
If 2-DG and 6-AN blocked the pathways which provide the requisite substrates for GlcCer
production, then treatment of cells with these inhibitors should cause a significant decrease in the
total GlcCer levels. Ceramide, GlcCer and lactosylceramide levels were measured via HPLCMS/MS following 8-hour treatment with 2-DG, 6-AN and ABT-263 alone or in combination.
Increases in intracellular ceramide are a hallmark of apoptotic cell induction [62, 64]. Indeed,
following treatment with ABT-263, which induces cell death through induction of mitochondrialinduced apoptosis, ceramide levels significantly increased. Furthermore, upon addition of 2-DG
or 6-AN, ceramide levels synergistically increased compared to ABT-263 alone. As expected, 2DG or 6-AN alone did not significantly increase ceramide levels, given that at low concentrations
they inhibit cell growth rather than induce apoptosis [119]. Notably, however, 2-DG and 6-AN
caused a dramatic drop in GlcCer levels by 45% and 23%, respectively, a decrease further
augmented by addition of ABT-263 (an additional 20% and 40%, respectively) (Fig. 9). The role
of lactosylceramide in cell death is not as clear, however it is worth noting that treatment with 6AN, not 2-DG, decreased lactosylceramide levels, as well (Fig. 9).
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These data further support the hypothesis that both glycolysis and the PPP are instrumental in
providing substrates for GlcCer formation. Furthermore, nutrient deprivation via metabolic
inhibition synergizes with ABT-263 in inducing cell death via ceramide accumulation within the
cell, data which is consistent with many other studies showing that metabolic inhibition of cancer
cells primes for cell death induction via cytotoxic inhibitors [53, 54, 120].
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Figure 2: FL5.12 cells overexpressing GLUT1 and HK1 are highly glycolytic.
a) FL5.12 HG cells stably overexpress glycolytic enzymes GLUT1 and HK1. Overexpression of integral
membrane protein GLUT1 and HK1 was confirmed by western blot. HK1 is not endogenously expressed in
wild-type FL5.12 cells. b) FL5.12 WT and HG cells were grown in glucose-free media for one hour,
incubated with 14C 2-Ddeoxy-glucose for one hour, then collected and counted by scintillation. FL5.12 HG
cells took up significantly more glucose than their WT counterparts. d) FL5.12 cells were treated for 48
hours with 1 mM 2-DG and cell viability was measured using Alamar Blue reduction. Graph B represents
duplicate samples, n=2.
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Figure 3: Glucosylceramide levels are elevated in a model of highly glycolytic cells.
a) Cellular lipids were harvested from FL5.12 cells growing in log phase. Glucosylceramide levels were
determined by HPLC-MS/MS. HG levels were normalized to WT. b) FL5.12 wild-type cells were glucosedeprived for 18 hours and the total amount of cellular glucosylceramides was determined by HPLCMS/MS. c) FL5.12 cells were grown for 24 hours in log phase with complete media then analyzed for
expression of GCS and GBA via qPCR. WT expression was set to 1.0 and HG expression was normalized
to wild-type. GCS and GBA expression decreased compared to wilt-type cells. d) GCS activity was
measured in FL5.12 wild-type and HG cells. Cells were grown in complete media for 2 hours and then
analyzed for GCS activity via addition of NBD-ceramide and separation on TLC. Graphs B and D represent
duplicate samples, n=2.
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Figure 4: Inhibition of FL5.12 cells with metabolic inhibitors depletes GSLs.
Cells were treated for 48 hours with a) 2-DG (0.06-150 mM) or b) 6-AN (0.06-135 μM) then measured for
cell viability via AlamarBlue reduction. HG cells are more resistant to treatment with HK-1 competitive
inhibitor 2-DG vs wild-type cells (IC50=0.33 mM vs 1.7 mM for wild-type and HG, respectively, at 48
hours). No significant different was seen in response to 6-AN treatment (IC50=2.9 μM vs 2.6 μM for WT
and HG, respectively). c) FL5.12 cells were treated with 2-DG or 6-AN at their respective IC50 for 8 hours.
Total hexosylceramide levels were determined via HPLC-MS/MS. Long-chain ceramides (C16-20) and
very long chain ceramides (C22+) are shown. Lipids levels were normalized to viable cell number.
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Figure 7: Preincubation with GCS Inhibitors confers resistance to doxorubicin in leukemia cells.
U937 cells were treated with a) increasing doses of doxorubicin (0.3-670 nM) alone or in combination with
PPMP IC30 (11 μM); b) increasing doses of PPMP (4.1-30 μM) in combination doxorubicin IC30 (21 nM);
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inhibitor of anti-apoptotic BCL2 proteins.
a,b) U937 cells were incubated for 48 hours with a) increasing doses of 2-DG plus either vehicle or ABT263 IC30 (5 μM) or b) increasing doses of ABT-263 plus vehicle or the IC30 of 2-DG (1.7 mM) for 48
hours. The relative number of viable cells was determined using reduction of AlamarBlue reagent. c,d)
U937 cells were incubated for 48 hours with c) increasing doses of 6-AN plus vehicle or IC30 (5 μM) of
ABT-263 or d) increasing doses of ABT-263 plus vehicle or the IC30 of 6-AN for 48 hours. Cell viability
was determined using reduction of AlamarBlue reagent. Doses: 2-DG: 33 μM to 170 mM; 6-AN: 13.3 nM
to 170 uM; ABT-263: 2.7 nM to 18 uM.
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Figure 9: Inhibitors of glycolytic metabolism and the pentose phosphate pathway synergize with an
inhibitor of anti-apoptotic BCL2 proteins to increase ceramide:glycosphingolipid ratios.

a) U937 cells were treated with vehicle (DMSO), ABT-263 IC30 (5 μM), 6-AN IC30 (1.7 μM), or the
combination of 6-AN and ABT-263 at their respective IC30 8 hours. Cells were harvested and lipids were
analyzed via HPLC/MS-MS. b) U937 cells were treated vehicle (DMSO), ABT-263 IC30 (5 μM), 2-DG
IC30 (5 mM), or the combination of 2-DG and ABT-263 at their respective IC30. Cells were harvested and
lipids were analyzed via HPLC/MS-MS.
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DISCUSSION
There exists a limited amount of data linking glucose availability in cells to production of
glycosphingolipids (GSLs), the seminal work being performed by the Shayman Group [38, 39] in
rat models of DM1. Furthermore, this phenomenon has never been shown outside of a metabolic
disease state. In the present study we have shown that there exists a definitive link between
glucose availability and GSL formation, independent of aberrant intracellular signaling pathways
of cancer cells or the influence of the extracellular environment present in disease states. Glucose
transporter 1 (GLUT1) and Hexokinase II (HK2) are often overexpressed in response to
oncogenic signaling pathways to support the highly glycolytic nature of the cancer cell [121,
122]. Our model of highly glycolytic cells, FL5.12 HG, overexpressed the same enzymes in a
non-transformed hematopoietic cell line (Fig. 2A), which increased glucose availability (Fig. 2B)
and significantly elevated GlcCer levels (Fig. 3A). On the other hand, glucose withdrawal in
wild-type FL5.12 cells correspondingly decreased GlcCer below baseline levels (Fig. 3B), thus
supporting our hypothesis that glucose availability in and of itself can directly influence
glycosphingolipid levels. We found that this is primarily a substrate-driven process, given that
neither expression nor activity of GCS, the enzyme responsible for GlcCer formation, was
significantly altered between the two cell lines.
It is taken as canon in cancer biology that a hallmark of neoplastic cells is reliance on aerobic
glycolysis over oxidative phosphorylation. In order to support the increased utilization of aerobic
glycolysis for production of ATP, many cancers, solid tumors and blood cancers inclusive, also
take up elevated amounts of glucose [3, 6, 9]. A growing body of evidence that suggests one of
the main advantages of and reliance on aerobic glycolysis is the production of intermediates for
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shunting into bioenergetic and anaplerotic pathways. Production of such substrates serves to
support the requisite increase in biomass of the rapidly dividing cell. For example, increased flux
into the PPP results in increased nucleotide formation via production of ribose-5-phosphate. In
keeping the “biomass hypothesis”, we tested whether inhibition of two bioenergetic pathways,
glycolysis and the PPP, would result in decreased GSL levels. Indeed, treatment with 2-DG and
6-AN decreased hexosylceramide levels in both cell lines (Fig. 4C). These results suggested that
pathways downstream of glucose uptake may provide the requisite substrates for production of
hexosylceramides, namely GlcCer. Therefore, increased glucose uptake elevates flux into these
pathways and subsequently levels of these intermediates, thereby increasing GSL levels.
Leukemia and lymphoma are umbrella classifications for complex and heterogeneous groups
of bone marrow- and lymphatic-derived malignancies, respectively, each with its own unique
aberrations in cellular signaling and metabolic profiles. As such, we chose to study the
relationship between glucose metabolism and GSL levels irrespective of genetic background in a
panel of leukemia and lymphoma cell lines (U937, OCI AML3, RAJI, HEL) (Fig. 5A). Given that
cancer cells are already highly glycolytic in nature, it is not surprising that a significant difference
in glucose uptake was not observed between the leukemia cell lines (Fig. 5C), or that GlcCer
levels are not entirely dependent on its uptake, although from the data it could be inferred that
differential uptake may play a role. On the other hand, we found that GCS activity is significantly
increased in cell lines with elevated GlcCer levels. This is in contrast to FL5.12 HG cells, where
GlcCer levels directly correlated to glucose uptake, without significantly altering GCS expression
or activity. Overall, these data indicate that other mechanisms may be at play in transformed cells
in addition to regulation of substrate uptake and GCS enzyme expression, which may include
regulation of substrate activity. As the following data would indicate, this may be related to
preferential shunting of glucose into pathways essential for GlcCer and GSL production in cell
lines with elevated GSL levels.
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Prior data in our lab showed that PDMP, a ceramide analogue inhibitor of GCS, synergizes
with ABT-263, an inhibitor of pro-apoptotic BCL-2 like proteins, in inducing apoptosis in
leukemia cells [103]. In the present study we showed that both 2-DG and 6-AN, inhibitors of
glycolysis and the PPP, respectively, also synergized with ABT-263 in U937 cells. Furthermore,
treatment with 2-DG and 6-AN led to a significant reduction in GlcCer levels, which were further
decreased upon co-treatment with ABT-263. ABT-263 alone increased the pro-apoptotic lipid
ceramide, an effect which was significantly augmented upon addition of 2-DG or 6-AN. Notably,
neither 2-DG nor 6-AN increased ceramide levels significantly on their own, indicating that these
two metabolic inhibitors act synergistically to augment the effect of ABT-263.
On the basis of the observations that 1) increased glucose uptake leads to increased GSL
levels and 2) inhibition of metabolic pathways such as glycolysis and the pentose phosphate
pathway reduce GSL levels, we hypothesize that in addition to producing intermediates for
biosynthetic reactions which fuel the highly proliferative state of cancer cells, formation of these
substrates also serves to increase the production of glycosphingolipids via GCS. An overview of
the proposed mechanism is provided in Fig. 11. Briefly, through shunting into the PPP, glucose
provides intermediates such as ribose-5-phosphate for synthesis of nucleotides such as UTP.
Increased glucose uptake also leads to increased flux into glycogen synthesis [123], which forms
UDP-glucose from UTP and glucose. Increase in glucose availability has been previously shown
to increase intracellular UDP-glucose levels in the kidney in rat models of DM1 [112, 124], an
increase which was later shown to elevate GSL levels [38, 39]. In this work, it was hypothesized
that UDP-glucose is utilized by GCS to form GlcCer through its addition to ceramide in diabetic
conditions within the kidney (Fig. 10). Accordingly, we hypothesize that in highly glycolytic
cells, such as cancers, one role of increased glucose uptake is to form UDP-glucose for use by
GCS to form GlcCer, in an attempt to deplete ceramide levels and evade apoptosis. It is also
plausible that other pathways could play a role in GlcCer formation, such as generation of
NADPH for use as a cofactor in de novo ceramide synthesis. The PPP has also been implicated
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recently in the transformed phenotype of cancer cells [20]. Furthermore, glucose-derived
pyruvate is utilized by the TCA cycle in transformed cells for production of anaplerotic
intermediates such as citrate for fatty acid synthesis [4], a mechanism which would support an
increase in overall production sphingolipids, including GlcCer. Future work in this area will focus
on the exact substrates elevated in cancer cells in response to increased glucose availability for
GlcCer formation, although we speculate that these will include: UDP-glucose, palmitoyl-COA,
fatty acids, and NADPH.
Taken together, down what therapeutic road do the present results lead us? Current standard
of care in many cancers focuses on targeting the highly proliferative phenotype of cancer cells
with genotoxic drugs such as platinums, anthracyclines, and pyrimidine analogs, among others.
However, these therapies are limited by the near inevitability of acquired resistance and
metastatic relapse [125], often of a more aggressive phenotype and association with poor patient
outcome [126-129]. By utilizing therapeutics which do not rely on targeting rapidly dividing
cells, but instead which target other intrinsic properties of malignant cells, it may be possible to
avoid development of resistance or disease relapse. Such is the theory behind the combination of
2-DG and ABT-263, in that this treatment targets two independent weaknesses that are nearly
ubiquitous among cancer cells: dependence on aerobic glycolysis and overexpression/dependence
on an intracellular target. It has been shown that the anti-apoptotic subfamily of BCL-2 proteins
are overexpressed in a large amount of leukemia subtypes [118, 130]. The combinatory therapy of
2-DG and ABT-263 has already proven effective in vitro and in vivo in many tumor-based
malignancies [131], and we have now shown in the present study that this combination of
therapeutics could also serve as an effective treatment option in leukemias. Furthermore, it has
been shown that altered ganglioside expression in cancers [50, 74, 76, 132], particularly
upregulation of certain species such as GM3, is associated with a more aggressive and malignant
phenotype in some cancers [50], such as melanoma [71, 133, 134]. This increased GM3
expression has been shown to both increase resistance and negatively regulate apoptosis through
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a Bcl-2-mediated mechanism [135]. Accordingly, inhibition of GCS in a drug-resistant cell line
both reversed drug resistance and increase sensitivity to apoptosis through decreasing Bcl-2
expression [136]. Given this association and the data presented in the current study, it would
follow that treatment with the BCL2 proapoptotic family inhibitor ABT-263 may also function to
abate ganglioside-mediated resistance to treatment and apoptosis.

Figure 10: Proposed mechanism of glycosphingolipid production via formation of substrates
via glycolysis, the PPP and glycogenesis in highly glycolytic cells.
Certain leukemia cells take up elevated levels of glucose, leading to increased flux through
glycolysis and into the pentose phosphate pathway, glycogen synthesis, nucleotide biosynthesis
and the TCA cycle. We hypothesize that increased flux into these pathways leads to the
production of the rate-limiting substrates necessary for glycosphingolipid formation, namely,
fatty acyl CoA, UDP-glucose, and NADPH.
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CONCLUSIONS
Future Directions
The present work demonstrates a clear relationship between glycolytic metabolism and
(glyco)sphingolipid biosynthesis in the context of elevated glucose availability. Future work
would be based on strengthening this relationship and further characterizing its implication in
cancer therapeutics. Data presented herein led us to formulate the hypothesis that increased
glucose uptake results in elevated flux through glycolysis and the PPP, thereby forming the
requisite substrates for GSL synthesis. Measurement of the metabolites implicated in GSL
formation would be instrumental in supporting this hypothesis. The ensuing paragraphs will
outline proposed experiments for detection of substrate uptake, metabolite detection and
subsequent incorporation into GSLs. Unless otherwise indicated, “highly glycolytic cells” will be
collectively used to indicate a general phenotype of increased glucose availability in both
transformed and non-transformed cell types.
In addition to being a critical cellular antioxidant, NADPH plays a vital role as a
reducing agent in many biosynthetic pathways. We proposed that NADPH produced by increased
flux through the PPP in highly glycolytic cells aids in formation of GSLs, as it is used in both in
fatty acid synthesis and in de novo ceramide synthesis. Simple measurement of NADPH could be
performed using commercially available kits to observe the effect of glucose availability, as well
as the effect of metabolic inhibitors used herein, such as 2-DG, 6-AN and PDMP/PPMP, on
NADPH levels. If more detailed analysis of NADPH were required, a recently improved method
for NADPH redox detection using deuterium for isotope labeling has been published [137]. This
method utilizes 2H labeling and subsequent quantification via mass spectrometry or NMR,
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allowing for distinction between NADH and NADPH production. Additionally, contribution of
different subcellular locations to NADPH production can be determined using cellular
fractionation techniques preceding quantification. This would be of importance in establishing
whether putative increased NADPH in the ER, the site of de novo ceramide synthesis, plays a role
in increased GSL formation. It is worth nothing that studies have suggested elevated glutamine
metabolism may play as critical a role as the PPP in producing NADPH in neoplastic cells, thus it
may be beneficial to look at players in this pathway as well using similar mechanisms [4].
UDP-Glucose and ceramide are utilized by glucosylceramide synthase to produce
glucosylceramide. Data from animal models of DM1 have shown that UDP-glucose is elevated in
response to increased glucose uptake [38, 39]. We hypothesized that increased glucose flux in
highly glycolytic cells results in increased flux into glycogen synthesis, thereby increasing the
formation of the requisite UDP-glucose. This phenomenon would be expected to occur more
readily in neoplastic cells, which benefit from increased glycogen stores during times of stress or
starvation [29, 30]. The enzyme responsible for UDP-glucose production is UDP-glucose
pyrophosphorylase (or glucose-1-phosphate uridyltransferase) (UGP), which catalyzes the
reversible synthesis of UDP-glucose from glucose-1-phosphate and UTP, releasing a
pyrophosphate group. To determine the contribution of this pathway to GSL in highly glycolytic
cells, expression and levels of UGP could be measured in both HG and leukemia cells to
determine the effect of elevated glucose availability. I would also propose inhibition of UGP to
emulate “normal” levels, both pharmacologically and genetically, to determine the effect on GSL
levels. I suggest in both methods only partial reduction in UGP activity, seeing as UDP-glucose is
necessary for a myriad of cellular functions and therefore its complete inhibition may produce
exaggerated and off-target effects. Conversely, overexpression of the enzyme would further
confirm (or deny) the contribution of UGP to GSL production. If our hypothesis were correct,
inhibition of UGP would deplete GSL levels, while its overexpression would elevate them.
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Increased fatty acid synthesis to support the requisite increase in biomass demanded by the
neoplastic cell has also been described as a component of deregulated cancer cell metabolism.
Palmitoyl-CoA11 is utilized in the first step of de novo ceramide synthesis and is thus critical to
sphingolipid metabolism and GSL formation. I propose using radiolabeled

13

C-glucose to

examine its incorporation into palmitate and subsequently into sphingolipids and GSLs.
Following incubation with the radiolabeled substrate, quantification would be performed using
mass spectrometry or NMR.
In addition to elucidating the role of individual metabolites in GSL formation, I also propose
further confirmation of the role of individual pathways (i.e. glycolysis, the PPP, glycogen
synthesis) in the production of GSLs in highly glycolytic cells. This would be performed through
genetic inhibition and overexpression of the rate-limiting enzymes responsible for control of these
pathways: hexokinase (glycolysis), glucose-6-phosphate dehydrogenase (PPP) and glycogen
synthesis (glycogenesis). As previously discussed, I would suggest the use of partial knockdown
via RNAi in order to elicit more physiologically-relevant effects and to avoid the off target effects
of complete ablation of a metabolic pathway.
Some studies have suggested that the role of GCS inhibitors in sensitizing to cytotoxic and
metabolic drugs is actually attributed to their action on p-glycoprotein, rather than GCS [98, 107].
As such, I would also suggest use of more “specific” GCS inhibitors (i.e. of the imino sugar
subclass) to confirm the results attained herein and therein, so that future experiments can be
properly compared and performed.
Furthermore, future work would further explore the hypothesis that sphingolipid metabolism
can play a paradoxical role in drug resistance under certain conditions. Namely, evidence has
suggested that GCS inhibitors PDMP and PPMP play a cytoprotective role in combination with
daunorubicin when used at a sublethal doses [109], confirmed by preliminary data in our lab in

11

Palmitoyl-CoA: the CoA-charged version of palmitic acid, the first fatty acid produced by fatty acid
synthesis and most common fatty acid in mammals
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the present study. Namely, we would aim to determine if 1) data gathered in additional cancer cell
models (i.e. adherent vs non-adherent, given the role of cell-surface GSLs in adhesion) would
recapitulate the cytoprotective effect at sublethal doses previously published and herein, and 2)
the same cytoprotective effect would occur in response to treatment with lethal doses (IC30) of
PDMP/PPMP in combination with doxorubicin. If data suggest that sublethal doses are
cytoprotective and lethal doses synergistic/additive/null effect, studies would proceed in the
direction of investigating the molecular and metabolic basis underlying this effect. One
hypothesis could incorporate the effect of GCS inhibition on drug efflux and the cytoprotective
nature of p-glycoprotein. Briefly, it has been shown that p-glycoprotein is downregulated in
response to GCS inhibition [96], and upregulated in response to GCS overexpression [95].
Intuitively, depletion of GlcCer, a p-gp substrate, via GCS inhibition would lead to compensatory
upregulation of GCS to maintain GSL homeostasis. Given the suggested relationship between
GCS and p-gp, this could consequently result in increased p-gp levels and subsequent drug efflux.
While cancer cell models are efficient for elucidation of biochemical pathways at the basic
science level, they risk acquiring further mutations and differential phenotypes in addition to the
original cancer. As such, further investigation of this phenomenon in a mouse model utilizing
similar methods as described above (i.e. pharmacological and genetic inhibition of key metabolic
enzymes, manipulation of glucose uptake in specific subsets of cells, etc.) would be critical in
providing support for our hypothesis. Pulling from the in vitro studies, multiple facets of cancer
cell metabolism and inhibition thereof will be addressed. This work would then move into
analysis of patient-derived samples. Cancers should include hematological and solid tumor
cancers of a variety of classes to observe if the phenotype is consistent across the board, in
relation to the adherent nature of the cell. This is a critical consideration given the key role of
GSLs in cell-cell adhesion, migration and metastasis. A panel of diverse neoplasms will allow
comparison of our favorite metabolic pathways in the context of markedly different molecular
aberrations. Such is the main argument for personalized medicine and clinical characterization of
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the molecular and metabolic “traits” of cancer cells. I propose analyzing glucose uptake in the
same manner as the present study, followed by measurement of pertinent sphingolipid and GSL
species. Given that glutamine metabolism may also play a role in these cells, I would also suggest
performing glutamine uptake assays, as well. The aforementioned rate-limiting enzymes should
be analyzed for mRNA expression and protein levels via qPCR and western blot, respectively.
Finally, synergism assays as described herein, i.e. PDMP/PPMP in combination with the
respective cytotoxic drug, should be performed. All experiments should be compared to clinical
scores: stage/score, aggressiveness, responsiveness to therapy, metastatic or non-malignant, etc.
Finally, we would like to more fully characterize the role of 2-DG and the glycolytic pathway
in decreasing GSL levels, and if the decrease in GSL levels is a prerequisite for the synergistic
effect observed in the combinatory treatment of 2-DG and 6-AN with ABT-263. In order to
reconstitute GSL levels in the cell, we propose inhibiting GBA, the enzyme responsible for
degradation of GlcCer, which would result in increased GlcCer and upstream GSLs.
As a parting note, the future method of lipid quantification is worth discussing in brief.
HPLC-MS/MS is a very sensitive method for sphingolipid detection, given that in addition to
quantitating overall lipid levels, it has the ability to also differentiate by fatty acid chain length.
However, it can be extremely costly if outsourced, as is often the case. If a more cost-effective
alternative were needed, it would be possible to measure the cause-effect relationship of
inhibiting GSL production using flow cytometric analysis directed towards specific GSL
molecules, such as GM1 or GD3 [138]. Furthermore, less sensitive methods such as TLC, used
herein, are acceptable methods in combination with labeled substrates such as 13C-glucose.

Caveats/Weaknesses
The caveats of the present study are ones which should be addressed and accepted in all
works which aim to target aberrant signaling and/or metabolic pathways as a means of treatment.
Cancer cells are complex, multi-faceted, transformed versions of normal cells. No aberration
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exists in and of itself, and rarely is any alteration in and of itself the sole reason for the
transformation from normal to neoplastic. Signaling pathways are inherently interconnected and
we must treat them as such; inhibition of one pathway will most likely result in eventual
upregulation of another pathway; inhibition of one aspect of metabolism may result in increased
reliance on another aspect of metabolism to support cancer growth. While glucose availability
may impact GSL formation through the aforementioned pathways, the function of increased
glucose uptake and utilization is by no means solely for production of GSLs, just as elevation of
GSLs is most likely not the crippling Achilles heel of cancer. The goal of chemotherapeutics
should be in simultaneously targeting multiple weaknesses of cancer cells in order to kill as many
cells as possible in an attempt to avoid the inevitable resistance that will occur with single
treatments.
Furthermore, the present study discusses the use of metabolic inhibitors to target cells
addicted to aerobic glycolysis. This approach will indiscriminately target all rapidly dividing
cells, and thus be prone to the side effects of established chemotherapies. It has been suggested a
“therapeutic window” exists for such treatments [51], although more work needs to be conducted
to approve or disapprove this notion. It is possible that as nanotechnology advances, treatments
may be targeted directly towards tumors using membrane-associated antigens, and thus would
avoid the aforementioned off-target effects.
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ABBREVIATIONS
2-DG

2-deoxyglucose

6-AN

6-aminonicatinomide

FL5.12 HG

FL5.12 Hexokinase-I Glut-1

G6PD

Glucose-6-phosphate dehydrogenase

GlcCer

Glucosylceramide

GBA

β-Glucocerebrosidase

GCS

Glucosylceramide synthase

GLUT1

Glucose transporter-1

GSL

Glycosphingolipid

HPLC-MS/MS

High performance liquid chromatography-mass spectrometry

HK1

Hexokinase-I

MDR

Multi-drug resistance

MDR1

Multidrug resistance gene

P-gp

P-glycoprotein

PPP

Pentose phosphate pathway

PDMP

1-phenyl-2-decanoylamino-3-morpholino-1-propanol

PPMP

1-phenyl-2-palmitoylamino-3-N-morpholine-1-propanol

S1P

Sphingosine-1-phosphate

SMase

Sphingomyelinase

TCA

Tricarboxylic acid cycle
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